港股異動 | 石四藥集團(2005.HK)急漲超12% 績後兩日累計升幅近17%
格隆匯8月26日丨石四藥集團(2005.HK)快速拉昇至12.44%,兩日累計升幅近17%。現報4.7港元,暫成交6742萬港元,最新總市值142.2億港元。石四藥集團8月25日公佈,上半年集團實現銷售收入17.83億港元;毛利11.41億港元,毛利率為64.0%;公司股權持有人應占溢利2.47億港元;每股基本盈利0.0815港元,宣派中期股息每股0.05港元。董事相信疫情過去之後,公司會迅速恢復持續增長態勢,目前公司的經營現金流充裕。此外,日前頭孢地尼膠囊及琥珀酸普蘆卡必利片中標第三批集採。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.